Company / Capital Expenditures
UroGen Pharma Ltd. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$289.0K
FY2025
5-year range
$194.0K / $752.0K
FY2021-FY2025
Trend
+49.0%
vs FY2024
Sector context
#152 of 194
Health Care
What the data says
UroGen Pharma Ltd.'s capital expenditures of $289,000 is lower than 78% of companies in the Health Care sector (FY2025). Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $289,000.
Based on SEC 10-K filings.
$289,000 in FY2025 with a 5-year CAGR of -2.3%.
Improved from $254,000 to $289,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -27.3%
- 5-Year CAGR
- -2.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 194This company $289.0K Sector average $117.5M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.3%, indicating a declining trend.
- In FY2025, capital expenditures increased 49.0% year-over-year.
- Ranks #152 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $289.0K | +49.0% |
| FY2024 | $194.0K | -23.6% |
| FY2023 | $254.0K | -66.2% |
| FY2022 | $752.0K | +0.0% |
| FY2021 | $752.0K | +131.4% |
| FY2020 | $325.0K | +19.9% |
| FY2019 | $271.0K | -51.6% |
| FY2018 | $560.0K | +106.6% |
| FY2017 | $271.0K | -61.0% |
| FY2016 | $695.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026